Sandesh Mahatme is CFO & VP at Sarepta Therapeutics, Inc. (SRPT). They have made 8 open-market trades across 1 company since 2013, most recently 2025-12-05.
CIK 0001511034
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $156K since 2013, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SRPT | SELL | 2019-12-13 | 2019-12-17 | $125.50 | $15.7M | -1.4% | -0.3% | -34.8% |
| SRPT | SELL | 2019-02-07 | 2019-02-08 | $145.00 | $9.4M | +5.0% | +3.4% | -8.5% |
| SRPT | SELL | 2019-01-31 | 2019-02-01 | $130.72 | $2.8M | -3.1% | +4.6% | -16.4% |
| SRPT | SELL | 2019-01-30 | 2019-02-01 | $130.23 | $8.5M | -3.1% | +4.6% | -16.4% |
| SRPT | SELL | 2018-10-24 | 2018-10-26 | $127.74 | $27.5M | +16.8% | +2.2% | -1.9% |
| SRPT | SELL | 2017-07-20 | 2017-07-21 | $41.00 | $2.0M | -10.7% | -16.2% | +19.0% |
| SRPT | SELL | 2016-10-17 | 2016-10-19 | $50.08 | $1.5M | -17.7% | -18.7% | -24.2% |
| SRPT | BUY | 2013-08-20 | 2013-08-20 | $31.10 | $156K | -15.4% | +0.6% | +0.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.